Primary Healthcare (PRY) – Sell
|Date of Report||ASX||Price||Price Target||Analyst Recommendation|
|Date of Report|
|Sector: Healthcare||52-Week Range: A$2.90 – 3.97|
|Industry: Healthcare Services||Market Cap: A$1,926.1m|
We rate PRY as a Sell due to the following reasons:
- The pace of recruitment and retention of healthcare professionals to be slower than expected. Significant changes to contracts with healthcare professionals that are unfavorable to PRY (and less beneficial to PRY’s bottom-line than in prior years).
- Management team in transition with new CEO due to commence.
- Competitive risk and market share loss to other listed and unlisted medical facility operators.
We see the following key risks to our investment thesis:
- Recruitment of healthcare professionals occurs at a faster than expected pace and on favorable contractual terms to PRY.
- Regulatory risk associated with changes to Government policy are clarified and to the benefit of PRY.
- PRY remains one of the major vertically integrated medical facility operators in Australia, with potential to improve operational leverage as GPs (and other health professionals) are recruited to the business.
- Near term risks are short lived and longer term, PRY benefits from attractive industry fundamentals (for instance, increasing aging population or population with chronic disease requiring medical care) with inflation proof and defensive earnings.
- Substantial shareholder, Jangho Group remains on the register which may lead to potential corporate activity (especially takeover at a premium).
Figure 1: PRY Revenue Split by Segment
Figure 2: PRY EBITDA Split by Segment
Since our sell recommendation, the share price has declined -25%. In our view, although underlying NPAT was broadly in line with last year and with guidance, Primary Healthcare (PRY) delivered results which were disappointing given revenue was up ~4.9%, EBITDA down -9.3%, EBIT down -4.4%.
Free cash flow, before growth capital expenditure, was $146.6m, an improvement on FY17. Final dividend of 5.5 cps, 100% franked, on a payout ratio of 60% of Underlying NPAT. Further, PRY announced a $250m capital raising. Offer issue price is $2.50 per new share, a 17.8% discount to theoretical ex-rights price of $3.04 on 17 August 2018. Retail entitlement offer opens on 27 August 2018 and closes on 7 September 2018. PRY trading halt is lifted on 22 August 2018.
For investors currently in the stock, if the share price before the close on 7 September 2018, appreciates significantly beyond $2.50, we recommend take up and sell (to receive the benefit of the arbitrage). Overall, we maintain our Sell recommendation.
- $250m capital raising and potential acquisition… PRY announced an underwritten $250m pro rata non-renounceable entitlement offer for 5.21 new shares at $2.50 per share (ex final FY 2018 dividend of 5.5cps). On completion PRY will have a pro-forma net debt/FY 2018 underlying EBITDA of 1.9x. PRY’s largest shareholder, Jangho Group, has provided an irrevocable commitment to subscribe for 100% of its pro rata share of offer. The funds will be used to
1. Over the next 3 years, invest ~$140m “to increase operational capacity in existing Medical Centres, deliver additional services and improve its ability to recruit and retain health care professionals in its Medical Centres division”;
2. Over the next 5 years, invest ~$100m to deliver a superior and differentiated Pathology infrastructure platform designed to increase operational efficiency, deliver significant clinical outcomes and support the continued growth of its Pathology Division.
3. PRY is in negotiations to acquire a leading day hospital operator with pro forma FY 2018 EBITDA of $7m for a total of ~$140m over a three-year period, including an upfront payment of $75m (if the acquisition proceeds) and future contingent payments related to operational milestones and performance. PRY is targeting greater than 15% return on investment from these projects.
- FY19 guidance with 1H19 expected to be weak. PRY’s management “expects underlying NPAT in FY19 to be at or above FY18 underlying NPAT, prior to the impact of the capital raising and potential acquisition…[further] based on current trading activity, industry growth is expected to be slower in 1H 2019 and then normalise to long‐term growth rates”.
- Pathology (~49% of EBITDA). The segment grew revenue by +5.0% despite the loss of the national bowel screening contract from January 2018 driven by growth in specialties such as histopathology, genetics and vets pathology. EBIT was up +4% when adjusted for the planned sale of the Healthscope collection centers. The segment was also able to reduce its property costs as a percentage of revenue, due to collections center rental negotiations.
- Medical centres (~32%% of EBITDA). Earnings (EBITDA) was down -22.9% as margins contracted from 38.6% in FY17 to 29.8%. On the analyst call, management pointed out the disappointing results but noted “we [are] near the bottom of profit contractions due to repositioning our GP contracts. There are only about a quarter of that cohort still on the old five-year contract. In terms of our GP numbers, we recruited a record 159 new GP this year, and have laid the foundations for strong successful recruitment in the future”.
- Imaging (~19% of EBITDA). Imaging division continued to see solid growth with EBIT up +16.6% on the back of an +10.5% increase in revenue driven by PRY’s “focus on the hospital and medical centers channels and on MRI and CT”.
PRY Results Summary
Figure 3: PRY Financial Summary
Figure 4: Peer group comparables – consensus
Figure 5: PRY Financial Summary
Source: BTIG, Company, Bloomberg
Primary Heath Care Ltd (PRY) operates 1) ~90 primary health care clinics in Australia. Its medical clinics are vertically integrated with family GPs, specialists, therapists; 2) ~90 pathology laboratories (along with ~800 specimen collection centres); and 3) over 160 diagnostic imaging centers. PRY offers different billing options through Medicare (Australia’s universal healthcare system) and bulk billing.
Recommendation Rating Guide
|Recommendation Rating Guide||Total Return Expectations on a 12-mth view|
|Speculative Buy||Greater than +30%|
|Buy||Greater than +10%|
|Neutral||Greater than 0%|
|Sell||Less than -10%|
Reach Markets Disclaimer
Reach Markets Pty Ltd (ABN 36 145 312 232) is a Corporate Authorised Representative of Reach Financial Group Pty Ltd (ABN 17 090 611 680) who holds Australian Financial Services Licence (AFSL) 333297. Please refer to our Financial Services Guide or you can request for a copy to be sent to you, by emailing email@example.com.
Read our full disclaimer here >
This publication contains general securities advice. In preparing the advice, Reach Markets Australia has not taken into account the investment objectives, financial situation and particular needs of any particular person. Before making an investment decision on the basis of this advice, you need to consider, with or without the assistance of a securities adviser, whether the advice in this publication is appropriate in light of your particular investment needs, objectives and financial situation. Reach Markets Australia and its associates within the meaning of the Corporations Act may hold securities in the companies referred to in this publication. Reach Markets Australia does, and seeks to do, business with companies that are the subject of its research reports. Reach Markets Australia believes that the advice and information herein is accurate and reliable, but no warranties of accuracy, reliability or completeness are given (except insofar as liability under any statute cannot be excluded). No responsibility for any errors or omissions or any negligence is accepted by Reach Markets Australia or any of its directors, employees or agents. This publication must not be distributed to retail investors outside of Australia.
It is recommended that you seek independent advice and read the relevant Product Disclosure Statement before making a decision in relation to any investment. Any advice contained in this communication is general and has not taken into account the investment objectives, financial situation and particular needs of any particular person.
Banyan Tree Disclaimer
This document is provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and Banyan Tree is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Banyan Tree does, and seeks to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Banyan Tree, its associates, officers, directors, employees and agents. Except for any liability which cannot be excluded, Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Banyan Tree is not liable to recipients in any matters whatsoever otherwise recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Banyan Tree does not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Banyan Tree.
This document has been commissioned by Reach Markets Australia Pty Ltd and provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).